In a significant stride for biotech innovation, Cambridge-based Cyted Health has secured $44 million in Series B funding to accelerate its mission of transforming early detection of esophageal cancer.
Unlock Full Access
Join our community of readers and never miss exclusive insights. Log in or create an account to continue reading.
